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Abstract
Regulatory/suppressor T cells (Tregs) maintain immunologic homeo-
stasis and prevent autoimmunity. In this article, past studies and
recent studies of Tregs in mouse models for lupus and of human
systemic lupus erythematosus are reviewed concentrating on
CD4+CD25+Foxp3+ Tregs. These cells consist of thymus-derived,
natural Tregs and peripherally induced Tregs that are similar
phenotypically and functionally. These Tregs are decreased in
young lupus-prone mice, but are present in normal numbers in
mice with established disease. In humans, most workers report
CD4+ Tregs are decreased in subjects with active systemic lupus
erythematosus, but the cells increase with treatment and clinical
improvement. The role of immunogenic and tolerogenic dendritic
cells in controlling Tregs is discussed, along with new strategies to
normalize Treg function in systemic lupus erythematosus.
Introduction
Systemic lupus erythematosus (SLE) is a disorder of immune
regulation characterized by the breakdown of tolerance to
self-nuclear, cytoplasmic and cell surface molecules and by
the production of autoantibodies to these elements. The
result is generalized autoimmunity manifested by multisystem
chronic inflammatory disease. Many T-cell and B-cell
abnormalities have been described, and these include
defects in the regulatory/suppressor T cells (Tregs) that
normally prevent pathologic self-reactivity. In the present
article, we shall review the literature on this topic in both
human lupus and animal models of this disease written before
and after the resurgence of interest in suppressor T cells in
the past decade. Treg abnormalities could contribute to T-cell
and B-cell hyperactivity in SLE for various reasons. These
include decreased numbers and/or inhibitory function of
these cells, increased resistance of effector T cells to
suppression, or greater expansion of effector T cells relative
to normal Tregs. Alternatively, the principal effect of Tregs on
T-cell function could be indirect by altering the properties of
antigen-presenting cells. Evidence for each of these
mechanisms will be discussed.
T cells with the ability to control autoantibody production
were first described by Teague and Friou in 1969. These
workers reported that the transfer of thymus cells from young
mice to old mice prevented the development of anti-
nucleoprotein antibodies, and also blocked their appearance
after immunization [1]. When the mitogen concanavalin A
was found to induce T cells to develop suppressive activity,
many workers reported decreased concanavalin A suppres-
sive activity in human SLE and mouse models [2,3]. Interest
in this topic diminished, however, until its renaissance in the
past decade. In 1996 Sakaguchi and coworkers noted that
3-day-thymectomized mice developed organ-specific auto-
immune disease [4]. This was because suppressor T cells
were depleted by neonatal thymectomy. Subsequently the
T cells were identified as CD4+ cells that expressed CD25,
the  α-chain of the IL-2 receptor. Similar multiorgan auto-
immune disease could also be produced by transferring
CD4+CD25– cells to immunodeficient mice, but this was
prevented by cotransfer of CD4+CD25+ cells [5].
It is now evident that Tregs consist of heterogeneous
populations of CD4 cells, CD8 cells and even natural killer
T cells [6]. Conveniently, the cells can be divided into those
that express the forkhead/winged helix transcription factor,
Foxp3, and those that do not. The latter include T regulatory 1
cells that produce predominantly IL-10, and or T helper 3
cells that produce predominantly transforming growth factor
beta (TGFβ). Foxp3+ Tregs are crucial for preventing auto-
immunity and keeping the immune system in homeostatic
balance. This transcription factor not only is responsible for
Treg differentiation, but also prevents these cells from
becoming Th17 proinflammatory effector cells. Depletion of
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only Foxp3+ Tregs in neonatal or adult mice results in massive
lymphoproliferation and rapidly fatal multisystem autoimmunity
[7]. Mutations of Foxp3 also result in severe autoimmune
syndromes in humans [8]. The present review will con-
centrate on Tregs that express Foxp3 since information about
T regulatory 1 cells and T helper 3 cells in SLE is very limited.
Information on invariant natural killer T cells in SLE has recently
been reviewed [9]. These cells also have an important role in
immune surveillance.
In the mouse approximately 5% of CD4+ cells are Tregs that
express Foxp3 [5]. In humans only 2% of CD4+ cells express
Foxp3, and these are the most brightly staining CD25+ cells
[10]. Foxp3 is unfortunately not a reliable marker of human
Tregs because activated CD4+ cells can transiently co-
express this transcription factor [11,12]. Besides naturally
occurring, thymus-derived CD4+CD25+Foxp3+ cells (nTregs),
it is known that IL-2 and TGFβ can induce peripheral CD4+
cells to become Foxp3+ suppressor cells [13]. These
suppressor  cells are adaptive CD4+CD25+Foxp3+ cells
(iTregs), induced in peripheral lymphoid tissues [14]. It is now
apparent that both nTregs and Foxp3+ iTregs have a similar
phenotype and similar functional properties. The
CD4+CD25+Foxp3+ Tregs that circulate in the blood are
probably a mixture of both subsets since a marker to
distinguish these subsets is not available. Similarities and
differences between Foxp3+ nTregs and Foxp3+ iTregs are
reviewed elsewhere [15]. Importantly, both IL-2 and TGFβ are
required for the maintenance of Foxp3 expression and for the
survival of both subsets [16,17]. Since production of both of
these cytokines is decreased in SLE [3], these defects
probably contribute to abnormalities of Foxp3+ Tregs as
described in the present review.
Regulatory T cells in mouse models of lupus
Natural Tregs have protective effects in lupus-prone mice
(Table 1). In the lupus-prone New Zealand mixed 2328 mice,
3-day thymectomy results in an early-onset, fatal glomerulo-
nephritis in females. The nephritis, however, largely regressed
in males, thereby revealing a checkpoint in lupus glomerulo-
nephritis progression that depends on gender. The transfer of
CD25+ nTregs from 6-week-old asymptomatic donors
effectively suppressed dsDNA autoantibody, but did not
protect the mice from the proliferative lupus glomerulo-
nephritis and sialoadenitis. Therefore, although nTregs have
some protective effects in New Zealand mixed 2328 mice,
these cells by themselves cannot control the disease. Other
Tregs are apparently needed for full protection [18].
The protective effects of endogenous CD4+CD25+ Tregs in
other mouse models are complex. Depletion of CD4+CD25+
cells in (NZB x NZW)F1 hybrid mice accelerated the onset of
glomerulonephritis [19]. In young BWF1 and/or SNF1 mice
that spontaneously develop a lupus-like disease, CD4+CD25+
nTregs are decreased before they develop glomerulonephritis
[20-22]. One group estimated that the pool of CD4+CD25+
cells in BWF1 mice is 40% to 50% that of phenotypically
normal mice [21]. This is important since all strains of lupus-
prone mice have B-cell abnormalities with hyperactive B cells
[23] and may also have hyperactive T cells with a low
threshold for activation [24]. On the other hand, the total
number of CD4+CD25+ cells is not reduced in older mice
that have developed lupus [20], and several groups have
found that the suppressor cell activity in vitro is intact in
lupus-prone mice [20,21,25]. Another group has reported
that T cells from MLR/lpr mice are resistant to T-cell suppres-
sion [25]. These cells may not be able to overcome the
strength of T-cell stimulation or the inhibitory effects of
proinflammatory cytokines produced by other cells. It is
known that strong Toll-like receptor stimulation triggered by
microbial infections results in IL-6 and other cytokines that
block Treg function [26]. nTregs may therefore not be able to
function normally in inflamed tissues.
The best evidence for the importance of Tregs in the
pathogenesis of SLE is that increasing the numbers of
Foxp3+ Tregs can alter the disease course. The adoptive
transfer of expanded CD4+CD25+ cells to BWF1 mice
delayed onset of the disease [20]. iTregs induced ex vivo
with IL-2 and TGFβ also have protective effects in lupus-like
syndromes. The transfer of parental DBA/2 spleen cells into
(DBA/2xC57/BL6)F1 mice results in a chronic graft versus
Table 1
Evidence that Foxp3+ regulatory T cells have protective effects in mouse models of lupus
Depletion of CD4+CD25+ cells in (NZB x NZW)F1 hybrid mice accelerated the onset of glomerulonephritis [19]
CD4+CD25+ natural or thymus-derived CD4+CD25+Foxp3+ cells are decreased in young BWF1 and/or SNF1 mice before they develop
glomerulonephritis [20,21,25]
Transfer of CD4+CD25+ cells from young lupus-prone mice have some protective effects on the development of the disease [18,20]
Immunization of BWF1 and/or SNF1 mice with tolerogenic peptides induce Foxp3+CD4+ and/or Foxp3+CD8+ regulatory T cells that produce
transforming growth factor beta and suppress the development of lupus [32-37]
The tolerogenic peptides generate tolerogenic transforming growth factor beta, producing plasmacytoid dendritic cells that expand both CD4 and
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host disease with high titers of anti-dsDNA autoantibodies
and a fatal immune complex glomerulonephritis. A single dose
of anti-donor iTregs prevented this syndrome and doubled
the survival of mice that had already developed anti-dsDNA
antibodies [27]. Polyclonal iTregs induced by stimulating
T cells with anti-CD3/CD28-coated beads with IL-2 and TGFβ
have also been recently found to have protective effects in
this model and other mouse models of autoimmune disease
[28]; in a collaboration with Antonio La Cava and Bevra Hahn at
UCLA, we have found these polyclonal iTregs also have protec-
tive effects in the BWF1 model (unpublished observations).
SLE is characterized by high levels of IL-6; this cytokine can
interfere with the function of Tregs [26], and can even
convert nTregs to IL-17-producing cells [29]. IL-17 levels
have been reported to be increased in SLE [30]. iTregs
induced by IL-2 and TGFβ, however, are resistant to this
effect of IL-6. This cytokine combination downregulates IL-6
receptor expression and signaling [31].
Immunization with peptides derived from nuclear autoantigens
or VH complementarity determining region sequences derived
from pathogenic anti-DNA antibodies can suppress the
development of lupus [32-35]. One group reported that high-
dose intravenous administration of a small ribonucleoprotein
peptide to BWF1 mice resulted in IL-10-producing Tregs that
delayed the onset of lupus [36]. Two groups have shown
therapeutic effects following nasal or subcutaneous
immunization of BWF1 and/or SNF1 mice with a tolerogenic
histone H4 peptide 471-94, described by Datta and
colleagues [37]. Wu and Staines reported that intranasal
immunization increased the numbers of CD4+CD25+ cells
and decreased the T-cell proliferative response to this
peptide [33]. Datta’s group reported that low-dose peptide
subcutaneous immunization induces SNF1 mice to develop
Foxp3+CD4+ and Foxp3+CD8+ Tregs that produce TGFβ,
resulting in a delay of glomerulonephritis and prolonged
survival [32]. Similarly, mice immunized with low doses of an
artificial V(H) peptide that contains T-cell determinants (called
pConsensus) results in CD4 and CD8 Tregs that each
expressed Foxp3. These Tregs blocked production of anti-
DNA antibodies and prolonged survival [38,39].
Overproduction of type I interferons in SLE matures dendritic
cells (DCs) into immunogenic antigen-presenting cells that
strongly contribute to the T-cell and B-cell hyperactivity
characteristic of this disease [40]. An imbalance between
immunogenic and tolerogenic DCs in SLE probably limits the
expansion of Tregs and can account for the decreased
numbers of these cells. The remaining Tregs cannot over-
come the strong T-cell stimulation provided by immunogenic
DCs. This imbalance, however, is reversible. Before SNF1
mice were given tolerogenic peptides, plasmacytoid DCs
from these mice produced high levels of IL-6 and their T cells
produced IL-17. Following immunization with tolerogenic H4
471-94 peptides, however, plasmacytoid DCs instead
produced high amounts of TGFβ, and autoantigen-specific T
cells no longer produced IL-17 [32]. The balance between
tolerogenic and immunogenic DCs can therefore be restored
in a mouse model of SLE (see Figure 1).
Regulatory T cells and dendritic cells in
human SLE
In the past it had been generally believed that decreased
numbers and/or function of Tregs contribute to the T-cell and
B-cell hyperactivity characteristic of SLE. During the 1970s
and 1980s when suppressor cells were considered to be
principally CD8+ cells, many groups reported decreased
functional activity [3]. A recent study has also documented
impaired CD8+ cell suppressive function in SLE [41]. With
the shift in attention from CD8+ Tregs to CD4+ Tregs, pub-
lished studies of CD4+CD25+ cells and CD4+Foxp3+ cells in
human SLE have been apparently contradictory.
Early reports of CD4+CD25+ T cells in human SLE revealed
decreased numbers of this subset (Table 2) [42-45]. Foxp3
expression and suppressive activity was then revealed to be
concentrated in the CD4 fraction staining brightly for CD25
[10]. Eight groups subsequently reported decreased
percentages of CD4+CD25highFoxp3+ Tregs in SLE [22,46-
52]. Four of these groups reported an inverse correlation
between percentages of CD4+CD25+ cells and disease
activity [47,49-51]. Two groups published sequential studies
that revealed an increase in CD4+CD25high cells in patients
when the disease became inactive [49]. CD4+CD25high cells
also increased following various treatments that included
corticosteroid therapy [53], therapeutic plasmapheresis [54],
or B-cell depletion with Rituximab therapy [55,56]. Since the
total number of T cells in patients with active SLE is generally
decreased, the absolute numbers of circulating
CD4+CD25high cells would also be decreased.
Two contrary reports have recently appeared documenting
that CD4+CD25high cells in SLE are similar to those of healthy
donors [57,58]. A third group reported that although the
percentage of CD4+CD25high cells in SLE in patients with
active disease was normal, the relative number of these Tregs
was actually decreased because of a greater expansion of
effector T cells [59].
As with the numbers of CD4+CD25+ cells, most workers
have found suppressor function in human SLE to be
abnormal. Several groups have reported in addition to
decreased CD4+CD25high Tregs that the suppressive activity
in vitro was also decreased [47,48,50,57]. Most of these
groups attributed the defects to the Tregs, but one group
reported increased resistance to suppression [57]. This
resistance positively correlated with disease activity. Although
this group attributed this resistance to decreased sensitivity
of responder T cells to suppression, they did not exclude the
possibility that excessive costimulation by autologous SLE
accessory cells included in the cultures was responsible for
Available online http://arthritis-research.com/content/10/6/227this finding. Consistent with this explanation, another group
reported that SLE responder cells can be inhibited by Tregs
in an assay that did not contain accessory cells [50].
Some discrepant reports of suppressive activity of Tregs in
SLE have appeared. A group that reported decreased Treg
percentages in SLE found that the inhibitory function of these
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Figure 1
T-cell/dendritic cell interactions in health and in systemic lupus erythematosus. Regulatory T cells (Tregs) (red) and effector T cells, shown as
potentially pathogenic anti-self T cells (blue), can affect the maturation of immature dendritic cells (DCs) to immunogenic or tolerogenic antigen-
presenting cells. Transforming growth factor beta (TGFβ) and IL-10 produced by Tregs promote tolerogenic DCs, and IFNγ or IL-17 produced by
effector T cells promotes immunogenic DCs. Toll-like receptor (TLR) 7 and TLR9 stimulation by apoptotic bodies in systemic lupus erythematosus
(SLE) results in type 1 interferon production, which promotes immunogenic DCs that activate potentially pathogenic self-reactive T cells. The
feedback loop shown sustains immunogenic DCs and, secondarily, results in decreased Tregs.
Table 2
Regulatory T cells in human systemic lupus erythematosus
Regulatory T cell subset Comment
CD4+CD25+ cells
Decreased [42-45]
CD4+CD25high cells Inverse correlation with lupus activity [44,47,49,50,52]
Decreased [22,46-52]
Similar to healthy donors [57,58,65]
Increase with treatment and disease improvement
Corticosteroids [53]
Plasmapheresis [54]
Rituximab [55,56]
CD4+Foxp3+ cells
Decreased [46,48,50] Inverse correlation with disease activity [46,48,50]
Similar to healthy donors [57]
Increased [47,61-63] Positive correlation with disease activity [47,61-63]
Suppressive activity in vitro
Decreased [48,50,57,62] (one-third of patients [60]) Decrease largely due to IFNγ released by patient antigen-presenting 
cells [62]
Not decreased [49] Decreased due to resistance of systemic lupus erythematosus 
responder or accessory cells [57]cells was normal [49]. Another group reported normal per-
centages of Tregs in SLE but found decreased suppressive
function in approximately one-third of the patients [60]. The
reasons for discrepant results include heterogeneous patient
populations, the effects of treatment on the subjects studied,
and technical differences such as the presence or absence of
accessory cells in the assays (see above).
Studies of CD4+Foxp3+ cells in SLE have been even more
variable that those on CD4+CD25+ cells. Two groups have
reported decreased CD4+CD25+Foxp3+ cells that correlated
inversely with disease activity [48,50]. One other group
reported decreased CD4+CD25+Foxp3+ cells in SLE without
any correlation with disease activity [46]. Three other studies
have reported normal values for CD4+CD25+Foxp3+ cells
[57-59]. Surprisingly, during the past year four separate
groups have reported increased percentages of CD4+ Foxp3+
in lupus and found that this result correlated with disease
activity [47,61-63]. Here Foxp3 was not only expressed by
CD4+CD25+cells, but also by CD4+CD25–Foxp3+ cells. In
our studies of untreated SLE patients admitted to the Los
Angeles County/University of Southern California Medical
Center for active SLE, we have generally found normal or
increased percentages of CD4+CD25highFoxp3+ cells and
have found that CD25–Foxp3+ cells are also increased.
Although Foxp3 is a reliable marker of Tregs in mice, it has
become evident that conventional human CD4+ cells can
transiently express this transcription factor when they are
activated [11]. Thus, the controversial results concerning
percentages of Foxp3+ CD4+ cells and correlations with
disease activity in SLE may be explained by a variability of
disease activity in the patients studied. Investigators who
reported decreased percentages probably studied patients
with chronic, moderately active disease and the percentages
of these Foxp3+ CD4+ Tregs increased with treatment and
disease improvement. By contrast, investigators who
reported increased Foxp3+ CD4+ cells probably studied
patients with more acutely active disease. These cells
included activation-induced Foxp3+ CD4+ nonTregs which
became Foxp3– as the disease became less severe. The
CD4+CD25–Foxp3+ cells remain to be characterized
CD127, the α-chain of the IL-7 receptor, has been found a
useful marker to discriminate between CD4+ regulatory and
effector cells [64]. Both naïve and most previously activated
CD4+ cells stain brightly for CD127. Although most human
CD4+CD25highFoxp3+ Tregs are previously activated memory
cells, this marker has been downregulated and these cells have
become CD127dim. Two groups have studied CD4+CD127dim
cells in SLE. One study confirmed that suppressive activity in
CD4+CD25+ cells in SLE was predominantly contained in the
CD127dim subset [57]. The other group reported that although
the percentage of CD127dim cells  in SLE was similar to that in
healthy controls this subset was relatively decreased because
of expansion of activated CD4+CD25+ effector cells [59].
Another problem with measurements of Tregs in humans is
that the numbers circulating in the blood may not correlate
with the numbers and function of these cells in the tissues.
There is very limited information concerning Foxp3+ Treg
numbers in lymphoid organs and in the tissues of patients
with SLE. One group has reported decreased Foxp3+ cells in
a lymph node from a patient with active SLE and in mRNA
isolated from the kidneys of five patients [49]. Another group
found decreased numbers of Foxp3+ cells in the skin of
patients with cutaneous lupus erythematosus. The number of
circulating Foxp3+ cells in these patients was normal [65].
Dysfunctional DCs in human SLE have also been described.
Monocyte-derived DCs from lupus patients displayed an
abnormal phenotype characterized by accelerated differen-
tiation, maturation and secretion of proinflammatory cyto-
kines, suggesting they are in a preactivated state [66,67] –
although not all workers agree [68]. The numbers of
plasmacytoid DCs in the blood were reduced, but these cells
accumulated in the kidney suggesting increased migration to
the tissues [69]. Yan and coworkers have evidence that
suggests antigen-presenting cells are responsible for Treg
defects in SLE [62]. These authors reported increased
circulating CD4+CD25+Foxp3+ cells that positively corre-
lated with disease activity, and the suppressive function of
these cells was intact in cultures without antigen-presenting
cells. The functional activity of both patient and healthy
control Tregs, however, was decreased in the presence of
the patient’s antigen-presenting cells. Moreover, IFNα
produced by these antigen-presenting cells strongly contri-
buted to the defective function. These findings are consistent
with the evidence of the important role of type I interferons in
the pathogenesis of SLE. The suppressor cell defects
described were therefore probably secondary to the resulting
imbalance between immunogenic DCs and tolerogenic DCs.
Conclusions and future directions
The studies reviewed above are consistent with the view that
decreased numbers and/or function of Foxp3+ Tregs
contribute to the pathogenesis of SLE. In mouse lupus, this
evidence included decreased numbers of Foxp3+ Tregs in
the early stage. Although Tregs are present in adequate
numbers in the tissues of animals with established disease,
they are unable to terminate chronic inflammation for reasons
that may include increased levels of IL-6. Nonetheless, the
adoptive transfer of nTregs or iTregs alters the SLE disease
course, and the administration of tolerogenic peptides to
young lupus-prone mice results in increased numbers of
Foxp3+CD4+ and Foxp3+CD8+ iTregs that have protective
effects.
In human lupus the evidence that Treg defects play a major
role in the perpetuation of this disease is only suggestive.
Studies of Tregs in SLE are mostly limited to blood lympho-
cytes and although there is considerable evidence that that
CD4+CD25high cells are decreased, not all workers agree.
Available online http://arthritis-research.com/content/10/6/227
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cells in the fraction of CD4+CD25+ cells measured. Two
groups, however, have reported normal percentages of
CD4+CD127dim cells, a subset that probably excludes most
of these contaminating cells [57,58]. The possibility remains
that Tregs are relatively decreased due to expansion of
effector T cells [59]. Most workers have found decreased
suppressor T-cell activity in SLE, but here also contradictory
reports have been published. Rather than a true functional
defect, defective suppressive activity could reflect increased
resistance of responder T cells to suppression or increased
costimulatory activity of antigen-presenting cells (Table 2).
Even those who report decreased suppressor T-cell function
have observed some activity of these cells in SLE because
the T-cell response to stimulation was augmented when
Tregs were removed [58].
Further information is needed in several areas. While in mice
it has been well documented that IL-2 and TGFβ can convert
naïve CD4+CD25– T cells to CD25+Foxp3+ suppressor cells,
similar conversion in humans is more complex. In both mice
and humans, suppressive nTregs can become proinflam-
matory IL-17-producing cells [29,70]. iTregs in mice induced
ex vivo with IL-2 and TGFβ are resistant to this conversion
[31], but in humans this has yet to be demonstrated. The
cytokine and gene expression profile of Foxp3+ Tregs in SLE
in comparison with healthy subjects has yet to be defined.
The functional properties of nTegs and iTregs need to be
better characterized, and more information is also needed
about CD8+ suppressor cells in SLE. It is difficult to draw
meaningful conclusions about the Treg functional activity
from assays based upon the suppression of T-cell
proliferation  in vitro. Tregs also inhibit T-cell migration,
differentiation and apoptosis. Moreover, the principal target of
Treg activity is probably antigen-presenting DCs rather than T
cells [71,72]. In addition, Tregs may have direct suppressive
effects on B cells [73], on natural killer cells [74,75] and on
osteoclasts [76,77].
The contact-dependent mechanism of action of CD4+Foxp3+
Tregs also remains poorly understood. TGFβ has an essential
role since effector T cells that cannot respond to this cytokine
fail to be inhibited [78]. How human Tregs convert the latent
precursor to its biologically active form remains to be
clarified. Other molecules that regulate Treg function include
cytotoxic T-lymphocyte antigen 4 [79], B7 family molecules
expressed on the cell surface [80], TNF family proteins [81],
and adenosine and its receptors [82,83].
It is evident in SLE that normal immunologic homeostasis has
been disrupted, with the balance strongly weighted towards
sustained T-cell reactivity. The two principal external mecha-
nisms that control T-cell reactivity, Treg suppression and
activation-induced apoptosis have failed. There is, however,
an important difference that distinguishes human lupus from
mouse lupus. In mice the course of the disease is steadily
downhill and fatal, whereas human disease is cyclic and
characterized by exacerbations and remission. Moreover
when patients enter remission, many of the abnormalities of
T cells and B cells improve [3]. This difference implies that at
least some feedback regulatory mechanisms in humans
become functional again as disease activity remits.
Other manifestations of disrupted immunologic homeostasis
in active SLE include impaired host defense. This abnormality
is probably the secondary sequelae of failed attempts to
control self-reactive cells. Finally, lymphocyte  production of
IL-2 and the mature form of TGFβ is decreased in SLE
(reviewed in [3]), and these are the cytokines required for the
growth and functional activity of Tregs.
An important goal in the management of human SLE is to
restore the balance between immunogenic and tolerogenic
DCs, and thereby to correct Treg numbers and function. In
active lupus, the products of the apoptotic cells that bind to
Toll-like receptor 7, Toll-like receptor 8, and Toll-like receptor
9 [84] expressed by DCs, and the proinflammatory cytokines
produced by activated T cells, continuously stimulate
immature DC to become immunogenic antigen-presenting
cells. These cells, in turn, activate more self-reactive T cells to
produce proinflammatory cytokines which sustain this
pathologic circuit (Figure 1). Strategies are needed to
interrupt this cycle and to drive the maturation of immature
DCs towards tolerogenic DCs that induce Tregs. Possible
approaches include treatment with anti-CD3 antibodies,
immunization with tolerogenic peptides, or the transfer of
autologous Tregs generated and/or expanded  ex vivo. As
stated above, the latter approach has been successful in
mice. Transfer of ex vivo expanded nTregs or of polyclonal
iTregs induced with IL-2 and TGFβ has had beneficial effects.
Besides controlling the activity of other T cells and B cells,
evidence has been obtained that these Tregs also induce
tolerogenic DCs in transplant tolerance [85]. In SLE once the
DC balance has been shifted back to tolerogenic
predominance, further stimulation of these tolerogenic DCs
with peptide autoantigens should expand or induce new
iTregs. Normalization of Treg numbers and function in
individuals with SLE has the potential to lead to remission of
this autoimmune disease.
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